

AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

1 – 21. (CANCELLED)

22. (CURRENTLY AMENDED) An isolated nucleic acid having at least 80% nucleic acid sequence identity to:

(a) a nucleic acid sequence amplified at least two fold in a cancer cell and encoding the polypeptide shown in Figure 4 (SEQ ID NO:7);

(b) a nucleic acid sequence amplified at least two fold in a cancer cell and encoding the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;

(c) a nucleic acid sequence amplified at least two fold in a cancer cell and encoding the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7);

(d) a nucleic acid sequence amplified at least two fold in a cancer cell and encoding the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;

(e) the nucleic acid sequence shown in Figure 3 (SEQ ID NO:6), amplified at least two fold in a cancer cell;

(f) the full-length coding sequence of the nucleic acid sequence shown in Figure 3 (SEQ ID NO:6), amplified at least two fold in a cancer cell; or

(g) the full-length coding sequence of the cDNA deposited under ATCC accession number 203661.

23. (CURRENTLY AMENDED) The isolated nucleic acid of Claim 22 having at least 85% nucleic acid sequence identity to:

(a) a nucleic acid sequence amplified at least two fold in a cancer cell and encoding the polypeptide shown in Figure 4 (SEQ ID NO:7);

(b) a nucleic acid sequence amplified at least two fold in a cancer cell and encoding the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;

(c) a nucleic acid sequence amplified at least two fold in a cancer cell and encoding the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7);

(d) a nucleic acid sequence amplified at least two fold in a cancer cell and encoding the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;

(e) the nucleic acid sequence shown in Figure 3 (SEQ ID NO:6), amplified at least two fold in a cancer cell;

(f) the full-length coding sequence of the nucleic acid sequence shown in Figure 3 (SEQ ID NO:6), amplified at least two fold in a cancer cell; or

(g) the full-length coding sequence of the cDNA deposited under ATCC accession number 203661.

24. (CURRENTLY AMENDED) The isolated nucleic acid of Claim 22 having at least 90% nucleic acid sequence identity to:

(a) a nucleic acid sequence amplified at least two fold in a cancer cell and encoding the polypeptide shown in Figure 4 (SEQ ID NO:7);

(b) a nucleic acid sequence amplified at least two fold in a cancer cell and encoding the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;

(c) a nucleic acid sequence amplified at least two fold in a cancer cell and encoding the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7);

(d) a nucleic acid sequence amplified at least two fold in a cancer cell and encoding the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;

(e) the nucleic acid sequence shown in Figure 3 (SEQ ID NO:6), amplified at least two fold in a cancer cell;

(f) the full-length coding sequence of the nucleic acid sequence shown in Figure 3 (SEQ ID NO:6), amplified at least two fold in a cancer cell; or

(g) the full-length coding sequence of the cDNA deposited under ATCC accession number 203661.

25. (CURRENTLY AMENDED) The isolated nucleic acid of Claim 22 having at least 95% nucleic acid sequence identity to:

(a) a nucleic acid sequence amplified at least two fold in a cancer cell and encoding the polypeptide shown in Figure 4 (SEQ ID NO:7);

(b) a nucleic acid sequence amplified at least two fold in a cancer cell and encoding the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;

(c) a nucleic acid sequence amplified at least two fold in a cancer cell and encoding the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7);

(d) a nucleic acid sequence amplified at least two fold in a cancer cell and encoding the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;

(e) the nucleic acid sequence shown in Figure 3 (SEQ ID NO:6), amplified at least two fold in a cancer cell;

(f) the full-length coding sequence of the nucleic acid sequence shown in Figure 3 (SEQ ID NO:6), amplified at least two fold in a cancer cell; or

(g) the full-length coding sequence of the cDNA deposited under ATCC accession number 203661.

26. (CURRENTLY AMENDED) The isolated nucleic acid of Claim 22 having at least 99% nucleic acid sequence identity to:

(a) a nucleic acid sequence amplified at least two fold in a cancer cell and encoding the polypeptide shown in Figure 4 (SEQ ID NO:7);

(b) a nucleic acid sequence amplified at least two fold in a cancer cell and encoding the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;

(c) a nucleic acid sequence amplified at least two fold in a cancer cell and encoding the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7);

(d) a nucleic acid sequence amplified at least two fold in a cancer cell and encoding the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;

(e) the nucleic acid sequence shown in Figure 3 (SEQ ID NO:6), amplified at least two fold in a cancer cell;

(f) the full-length coding sequence of the nucleic acid sequence shown in Figure 3 (SEQ ID NO:6), amplified at least two fold in a cancer cell; or

(g) the full-length coding sequence of the cDNA deposited under ATCC accession number 203661.

27. (PREVIOUSLY ADDED) An isolated nucleic acid comprising:

(a) a nucleic acid sequence encoding the polypeptide shown in Figure 4 (SEQ ID NO:7);

(b) a nucleic acid sequence encoding the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;

(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7);

(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;

(e) the nucleic acid sequence shown in Figure 3 (SEQ ID NO:6);

(f) the full-length coding sequence of the nucleic acid sequence shown in Figure 3 (SEQ ID NO:6); or

(g) the full-length coding sequence of the cDNA deposited under ATCC accession number 203661.

28. (PREVIOUSLY ADDED) The isolated nucleic acid of Claim 27 comprising a nucleic acid sequence encoding the polypeptide shown in Figure 4 (SEQ ID NO:7).

29. (PREVIOUSLY ADDED) The isolated nucleic acid of Claim 27 comprising a nucleic acid sequence encoding the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide.

30. (PREVIOUSLY ADDED) The isolated nucleic acid of Claim 27 comprising a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7).

31. (PREVIOUSLY ADDED) The isolated nucleic acid of Claim 27 comprising a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide.

32. (PREVIOUSLY ADDED) The isolated nucleic acid of Claim 27 comprising the nucleic acid sequence shown in Figure 3 (SEQ ID NO:6).

33. (PREVIOUSLY ADDED) The isolated nucleic acid of Claim 27 comprising the full-length coding sequence of the nucleic acid sequence shown in Figure 3 (SEQ ID NO:6).

34. (PREVIOUSLY ADDED) The isolated nucleic acid of Claim 27 comprising the full-length coding sequence of the cDNA deposited under ATCC accession number 203661.

35. (CURRENTLY AMENDED) An isolated nucleic acid, having at least 80% nucleic acid sequence identity to the complement of the full-length nucleic acid molecule of SEQ ID NO:6, that hybridizes to:

(a) a nucleic acid sequence amplified at least two fold in a cancer cell and encoding the polypeptide shown in Figure 4 (SEQ ID NO:7);

(b) a nucleic acid sequence amplified at least two fold in a cancer cell and encoding the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;

(c) a nucleic acid sequence amplified at least two fold in a cancer cell and encoding the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7);

(d) a nucleic acid sequence amplified at least two fold in a cancer cell and encoding the extracellular domain of the polypeptide shown in Figure 4 (SEQ ID NO:7), lacking its associated signal peptide;

(e) the nucleic acid sequence shown in Figure 3 (SEQ ID NO:6), amplified at least two fold in a cancer cell;

(f) the full-length coding sequence of the nucleic acid sequence shown in Figure 3 (SEQ ID NO:6), amplified at least two fold in a cancer cell; or

(g) the full-length coding sequence of the cDNA deposited under ATCC accession number 203661.

36. (PREVIOUSLY ADDED) The isolated nucleic acid of Claim 35, wherein said hybridization occurs under stringent conditions.

37. (CANCELLED)

38. (PREVIOUSLY ADDED) A vector comprising the nucleic acid of Claim 22.

39. (PREVIOUSLY ADDED) The vector of Claim 38, wherein said nucleic acid is operably linked to control sequences recognized by a host cell transformed with the vector.

40. (PREVIOUSLY ADDED) A host cell comprising the vector of Claim 38.

41. (PREVIOUSLY ADDED) The host cell of Claim 40, wherein said cell is a CHO cell, an *E. coli* or a yeast cell.